People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said ... are part of a wave of obesity medications known ...

Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

Lilly reported that the two drugs, which share the active ingredient tirzepatide, now account for 53.3% of the U.S. GLP-1 market. Despite strong performance, shares of Lilly fell more than 5% in ...

The World Health Organization (WHO) on Thursday announced its support for weight-loss drugs in adults globally. The organization plans to back GLP-1s like Wegovy and Zepbound to treat obesity in ...

Investing.com -- CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a more affordable price. Starting July 1, 2025, Wegovy will ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots, two of world’s biggest drugmakers — Eli Lilly & Co. and Novo ...

Nutrition-tracking platform Healthify is banking on weight-loss drugs to boost growth, anticipating demand for these medicines to boom in India. The company is increasing its offerings to ...